Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation Launch

Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing for a June launch of AUVELITY in Alzheimer's disease agitation while continuing to expand its push in major depressive disorder, citing broad payer access, a larger sales force and what they described as a differentiated clinical profile.

MarketBeat • May 12, 2026

Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

Axsome Therapeutics Recognizes Mental Health Month

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced its support for Mental Health Month alongside the broader mental health advocacy community. In recognition of this year's More Good Days Together theme, Axsome is sharing resources to support individuals affected by mental health conditions, their families, and the communities around them.

GlobeNewsWire • May 7, 2026

AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales

Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.

Zacks Investment Research • May 5, 2026

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in May:

GlobeNewsWire • May 5, 2026

Carillon Chartwell Small Cap Growth Fund: Q1 2026 Portfolio Movers

The information technology sector delivered some of the portfolio's strongest performance in the fourth quarter. A strong ramp-up of Coherent's optical transceivers sales drove strong growth in its networking segment. Macom Technology Solutions' strong third-quarter earnings addressed investor concerns related to margin volatility, leading to a rebound in the fourth quarter.

Seeking Alpha • May 5, 2026

Axsome Continues To Breakneck Pace On Solid First-Quarter Sales

Axsome stock jumped Monday on in-line first-quarter sales following FDA approval of Auvelity in Alzheimer's agitation on Friday.

Investors Business Daily • May 4, 2026

Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied

Axsome Therapeutics, Inc. is rated Hold, as revenue growth and pipeline promise are offset by sequential declines and ongoing losses. AXSM's Q1 revenues grew 57% year-on-year to $191m, but both Auvelity and Sunosi saw sequential sales declines. Management's peak revenue targets—over $18bn across the portfolio—appear highly ambitious given current product performance and competitive dynamics.

Seeking Alpha • May 4, 2026

Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript

Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 4, 2026

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY ® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth SUNOSI ® 1Q 2026 net product revenue of $33.9 million, representing 34% year-over-year growth SYMBRAVO ® 1Q 2026 net product sales of $4.1 million AUVELITY approved for the treatment of agitation associated with dementia due to Alzheimer's disease NDA for AXS-12 for the treatment of cataplexy in narcolepsy submitted to the FDA AXS-20 (balipodect), potentially first-in-class, pre-Phase 3, PDE10A inhibitor for schizophrenia and Tourette syndrome, added to pipeline Company to host conference call today at 8:00 AM Eastern NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the first quarter of 2026 and provided a general business update. “Axsome had a tremendous start to 2026.

GlobeNewsWire • May 4, 2026